Visit https://www.peervoice.com/HHK860 to view the entire programme with slides. After completing “New Targets in IBD: Focus on IL-23”, participants will be able to: Explain the rationale for targeting IL-23 in inflammatory bowel disease (IBD); Evaluate the relative efficacy and safety of IL-23 inhibitors to date for patients with IBD; and Describe how these agents may fit into future treatment algorithms for IBD.